Academic Journal
Incidence of Acute Kidney Injury in Relapsed and Refractory Multiple Myeloma treated with Teclistamab versus CAR T-cells
| العنوان: | Incidence of Acute Kidney Injury in Relapsed and Refractory Multiple Myeloma treated with Teclistamab versus CAR T-cells |
|---|---|
| المؤلفون: | Charkviani, Mariam, Brochero, Maria Jose Vargas, Mohan, Arjunmohan, Vaughan, Lisa E, Sandahl, Tyler B, De Menezes Silva Corrae, Andre, Lin, Yi, Leung, Nelson, Herrmann, Sandra M |
| المصدر: | Nephrology Dialysis Transplantation ; ISSN 0931-0509 1460-2385 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2025 |
| الوصف: | Background and Hypothesis Teclistamab, a novel bispecific monoclonal antibody targeting CD3 and B-cell maturation antigen (BCMA), and chimeric antigen receptor T-cell (CAR-T) therapy are promising options for treating relapsed/refractory multiple myeloma (MM). However, the rates of acute kidney injury (AKI) associated with teclistamab remain inadequately characterized. This study aims to compare the incidence, severity, and outcomes of AKI between patients receiving teclistamab and CAR-T therapy. Methods This was a retrospective study involving 64 patients with relapsed/refractory MM treated with either teclistamab or CAR-T therapy. All patients had previously received at least four lines of chemotherapy before being treated with either teclistamab or CAR-T. The primary outcome was the incidence of AKI, and secondary outcomes included AKI severity, kidney recovery rates, and mortality. Kaplan-Meier estimates for AKI-free survival were calculated, and hazard ratios (HRs) for AKI risk were determined using Cox proportional hazards models. Results Sixty-four patients met inclusion criteria for this study (30 received CAR-T and 34 received teclistamab therapy). Among these patients, 14 AKI events occurred in total (22%), with 10 events (29%) in the teclistamab group and 4 events (13%) in the CAR-T group. AKI-free survival estimates at 180 days after treatment initiation were 68% (95% confidence interval [CI]: 53%-87%) for teclistamab patients and 90% (95% CI: 79%-100%) for CAR-T patients. While patients receiving teclistamab were found to have an increased risk of an AKI event compared to those receiving CAR-T therapy, the results were not statistically significant (HR [95% CI]: 3.38 [0.93–12.31], P = 0.065). Conclusions This study suggests that patients treated with teclistamab may experience a higher incidence of AKI compared to those receiving CAR-T therapy. However, further research is required to determine whether this increased risk is attributable to disease progression or teclistamab itself. These ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/ndt/gfaf004 |
| DOI: | 10.1093/ndt/gfaf004/61430215/gfaf004.pdf |
| الاتاحة: | https://doi.org/10.1093/ndt/gfaf004 https://academic.oup.com/ndt/advance-article-pdf/doi/10.1093/ndt/gfaf004/61430215/gfaf004.pdf |
| Rights: | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model |
| رقم الانضمام: | edsbas.5CB09A43 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/ndt/gfaf004 |
|---|